Journal of Molecular Diagnostics最新文献_第7页

IF 3.4 3区医学

Journal of Molecular Diagnostics Pub Date : 2024-08-01 DOI: 10.1016/j.jmoldx.2024.05.003

引用次数: 0

Performance Evaluation of a Commercial Automated Library Preparation System for Clinical Microbial Whole-Genome Sequencing Assays 用于临床微生物全基因组测序测定的商用自动文库制备系统的性能评估。

IF 3.4 3区医学

Journal of Molecular Diagnostics Pub Date : 2024-08-01 DOI: 10.1016/j.jmoldx.2024.05.006

{"title":"Performance Evaluation of a Commercial Automated Library Preparation System for Clinical Microbial Whole-Genome Sequencing Assays","authors":"","doi":"10.1016/j.jmoldx.2024.05.006","DOIUrl":"10.1016/j.jmoldx.2024.05.006","url":null,"abstract":"<div><p>Next-generation sequencing (NGS) has proven clinical utility on disease management and serves as an important tool for genomic surveillance. Currently, hurdles surrounding its implementation, namely the complex and demanding analytical workflows, have impeded its widespread use in many laboratories. To address this challenge, the UCLA Molecular Microbiology and Pathogen Genomics Laboratory evaluated the performance of the Tecan MagicPrep NGS system, a commercial automated solution for library preparation for clinical whole-genome sequencing assays, against the Illumina Nextera DNA Flex Library Prep. Using 35 unique organisms (28 bacteria and 7 fungi) for various clinical applications, including microbial identification and genomic characterization, we compared the quantity and quality of the prepared libraries and the resulting sequences, and concordance of the overall results. We also assessed the impact of its implementation on laboratory workflow. The MagicPrep NGS produced higher library concentrations with smaller sizes, and correspondingly, higher molarity. Quality metrics of the sequences, however, demonstrated no significant impact on the overall results, producing 100% concordance with the reference method. Importantly, workflow analysis showed 5 hours less hands-on time per run with more flexibility. This evaluation study indicates that performance of the MagicPrep NGS is comparable to the Nextera DNA Flex with the added benefit of improving workflow efficiency and reducing labor for performing routine clinical microbial whole-genome sequencing tests.</p></div>","PeriodicalId":50128,"journal":{"name":"Journal of Molecular Diagnostics","volume":"26 8","pages":"Pages 719-726"},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1525157824001193/pdfft?md5=ec16f54f7fb1d2b797624fe26f3838ca&pid=1-s2.0-S1525157824001193-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141293861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Implementation of a High-Accuracy Targeted Gene Expression Panel for Clinical Care 在临床护理中实施高精度靶向基因表达检测。

IF 3.4 3区医学

Journal of Molecular Diagnostics Pub Date : 2024-08-01 DOI: 10.1016/j.jmoldx.2024.04.005

{"title":"Implementation of a High-Accuracy Targeted Gene Expression Panel for Clinical Care","authors":"","doi":"10.1016/j.jmoldx.2024.04.005","DOIUrl":"10.1016/j.jmoldx.2024.04.005","url":null,"abstract":"<div><p>This study describes the validation of a clinical RNA expression panel with evaluation of concordance between gene copy gain by a next-generation sequencing (NGS) assay and high gene expression by an RNA expression panel. The RNA Salah Targeted Expression Panel (RNA STEP) was designed with input from oncologists to include 204 genes with utility for clinical trial prescreening and therapy selection. RNA STEP was validated with the nanoString platform using remnant formalin-fixed, paraffin-embedded–derived RNA from 102 patients previously tested with a validated clinical NGS panel. The repeatability, reproducibility, and concordance of RNA STEP results with NGS results were evaluated. RNA STEP demonstrated high repeatability and reproducibility, with excellent correlation (<em>r</em> > 0.97, <em>P</em> < 0.0001) for all comparisons. Comparison of RNA STEP high gene expression (log2 ratio ≥ 2) versus NGS DNA-based gene copy number gain (copies ≥ 5) for 38 mutually covered genes revealed an accuracy of 93.0% with a positive percentage agreement of 69.4% and negative percentage agreement of 93.8%. Moderate correlation was observed between platforms (<em>r</em> = 0.53, <em>P</em> < 0.0001). Concordance between high gene expression and gene copy number gain varied by specific gene, and some genes had higher accuracy between assays. Clinical implementation of RNA STEP provides gene expression data complementary to NGS and offers a tool for prescreening patients for clinical trials.</p></div>","PeriodicalId":50128,"journal":{"name":"Journal of Molecular Diagnostics","volume":"26 8","pages":"Pages 685-699"},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141082655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative Analysis of Gene Expression Analysis Methods for RNA in Situ Hybridization Images RNA 原位杂交图像基因表达分析方法的比较分析。

IF 3.4 3区医学

Journal of Molecular Diagnostics Pub Date : 2024-07-26 DOI: 10.1016/j.jmoldx.2024.06.010

Valeria Ariotta , Eros Azzalini , Vincenzo Canzonieri , Sampsa Hautaniemi , Serena Bonin

引用次数: 0

Optimization of Tumor Dissection Procedures Leads to Measurable Improvement in the Quality of Molecular Testing 优化肿瘤解剖程序可显著提高分子检测的质量。

IF 3.4 3区医学

Journal of Molecular Diagnostics Pub Date : 2024-07-25 DOI: 10.1016/j.jmoldx.2024.06.009

Bryan L. Betz , Corey S. Post , Jennifer Bergendahl , Nanci Lefebvre , Helmut Weigelin , Noah A. Brown

{"title":"Optimization of Tumor Dissection Procedures Leads to Measurable Improvement in the Quality of Molecular Testing","authors":"Bryan L. Betz , Corey S. Post , Jennifer Bergendahl , Nanci Lefebvre , Helmut Weigelin , Noah A. Brown","doi":"10.1016/j.jmoldx.2024.06.009","DOIUrl":"10.1016/j.jmoldx.2024.06.009","url":null,"abstract":"<div><p>Molecular tests have an inherent limit of detection (LOD) and, therefore, require samples with sufficiently high percentages of neoplastic cells. Many laboratories use tissue dissection; however, optimal procedures for dissection and quality assurance measures have not been established. In this study, several modifications to tissue dissection procedures and workflow were introduced over 4 years. Each modification resulted in a significant improvement in one or more quality assurance measures. The review of materials following dissection resulted in a 90% reduction in <em>KRAS</em> mutations below the stated LOD (<em>P</em> = 0.004). Mutation allele frequencies correlated best with estimated tumor percentages for pathologists with more experience in this process. The direct marking of unstained slides, use of a stereomicroscope, validation of extraction from diagnostic slides, and use of a robust, targeted next-generation sequencing platform all resulted in reduction of quantity not sufficient specimens from 20% to 25% to nearly 0%, without a significant increase in test failures or mutations below the LOD. These data indicate that post-dissection review of unstained slides and monitoring quantity not sufficient rate, test failure rate, and mutation allele frequencies are important tumor dissection quality assurance measures that should be considered by laboratories performing tissue dissections. The amendments to tissue dissection procedures enacted during this study resulted in a measurable improvement in the quality and reliability of this process based on these metrics.</p></div>","PeriodicalId":50128,"journal":{"name":"Journal of Molecular Diagnostics","volume":"26 10","pages":"Pages 876-887"},"PeriodicalIF":3.4,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1525157824001624/pdfft?md5=7ea2902809fe522e8be547b057d149fb&pid=1-s2.0-S1525157824001624-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141789708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Network-Based Framework to Discover Treatment-Response–Predicting Biomarkers for Complex Diseases 发现复杂疾病治疗反应预测生物标志物的网络框架。

IF 3.4 3区医学

Journal of Molecular Diagnostics Pub Date : 2024-07-25 DOI: 10.1016/j.jmoldx.2024.06.008

Uday S. Shanthamallu , Casey Kilpatrick , Alex Jones , Jonathan Rubin , Alif Saleh , Albert-László Barabási , Viatcheslav R. Akmaev , Susan D. Ghiassian

{"title":"A Network-Based Framework to Discover Treatment-Response–Predicting Biomarkers for Complex Diseases","authors":"Uday S. Shanthamallu , Casey Kilpatrick , Alex Jones , Jonathan Rubin , Alif Saleh , Albert-László Barabási , Viatcheslav R. Akmaev , Susan D. Ghiassian","doi":"10.1016/j.jmoldx.2024.06.008","DOIUrl":"10.1016/j.jmoldx.2024.06.008","url":null,"abstract":"<div><p>The potential of precision medicine to transform complex autoimmune disease treatment is often challenged by limited data availability and inadequate sample size when compared with the number of molecular features found in high-throughput multi-omics data sets. To address this issue, the novel framework PRoBeNet (Predictive Response Biomarkers using Network medicine) was developed. PRoBeNet operates under the hypothesis that the therapeutic effect of a drug propagates through a protein-protein interaction network to reverse disease states. PRoBeNet prioritizes biomarkers by considering i) therapy-targeted proteins, ii) disease-specific molecular signatures, and iii) an underlying network of interactions among cellular components (the human interactome). PRoBeNet helped discover biomarkers predicting patient responses to both an established autoimmune therapy (infliximab) and an investigational compound (a mitogen-activated protein kinase 3/1 inhibitor). The predictive power of PRoBeNet biomarkers was validated with retrospective gene-expression data from patients with ulcerative colitis and rheumatoid arthritis and prospective data from tissues from patients with ulcerative colitis and Crohn disease. Machine-learning models using PRoBeNet biomarkers significantly outperformed models using either all genes or randomly selected genes, especially when data were limited. These results illustrate the value of PRoBeNet in reducing features and for constructing robust machine-learning models when data are limited. PRoBeNet may be used to develop companion and complementary diagnostic assays, which may help stratify suitable patient subgroups in clinical trials and improve patient outcomes.</p></div>","PeriodicalId":50128,"journal":{"name":"Journal of Molecular Diagnostics","volume":"26 10","pages":"Pages 917-930"},"PeriodicalIF":3.4,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1525157824001612/pdfft?md5=3259c4090584f8080a3f5dff87b12860&pid=1-s2.0-S1525157824001612-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141789706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genotype and Phenotype Correlation of Patients with Osteogenesis Imperfecta 成骨不全症患者基因型与表型的相关性

IF 3.4 3区医学

Journal of Molecular Diagnostics Pub Date : 2024-07-20 DOI: 10.1016/j.jmoldx.2024.05.014

Lamiya Aliyeva , Yasemin Denkboy Ongen , Erdal Eren , Mehmet B. Sarisozen , Adem Alemdar , Sehime G. Temel , Sebnem Ozemri Sag

{"title":"Genotype and Phenotype Correlation of Patients with Osteogenesis Imperfecta","authors":"Lamiya Aliyeva , Yasemin Denkboy Ongen , Erdal Eren , Mehmet B. Sarisozen , Adem Alemdar , Sehime G. Temel , Sebnem Ozemri Sag","doi":"10.1016/j.jmoldx.2024.05.014","DOIUrl":"10.1016/j.jmoldx.2024.05.014","url":null,"abstract":"<div><p>Osteogenesis imperfecta (OI) is the most common inherited connective tissue disease of the bone, characterized by recurrent fractures and deformities. In patients displaying the OI phenotype, genotype–phenotype correlation is used to screen multiple genes swiftly, identify new variants, and distinguish between differential diagnoses and mild subtypes. This study evaluated variants identified through next-generation sequencing in 58 patients with clinical characteristics indicative of OI. The cohort included 18 adults, 37 children, and 3 fetuses. Clinical classification revealed 25 patients as OI type I, three patients as OI type II, 18 as OI type III, and 10 as OI type IV. Fifteen variants in <em>COL1A1</em> were detected in 19 patients, 9 variants in <em>COL1A2</em> (<em>n</em> = 19), 5 variants in <em>LEPRE1/P3H1</em> (<em>n</em> = 7), 3 variants in <em>FKBP10</em> (<em>n</em> = 4), 3 variants in <em>SERPINH1</em> (<em>n</em> = 2), 1 variant in <em>IFITM5</em> (<em>n</em> = 1), and 1 variant in <em>PLS3</em> (<em>n</em> = 1). In total, 37 variants (18 pathogenic, 14 likely pathogenic, and 5 variants of uncertain significance), including 16 novel variants, were identified in 43 (37 probands, 6 family members) of the 58 patients analyzed. This study highlights the efficacy of panel testing in the molecular diagnosis of OI, the significance of the next-generation sequencing technique, and the importance of genotype–phenotype correlation.</p></div>","PeriodicalId":50128,"journal":{"name":"Journal of Molecular Diagnostics","volume":"26 9","pages":"Pages 754-769"},"PeriodicalIF":3.4,"publicationDate":"2024-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141724945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Strategic Implementation of Fragile X Carrier Screening in China 中国脆性 X 携带者筛查的战略实施：重点试点研究。

IF 3.4 3区医学

Journal of Molecular Diagnostics Pub Date : 2024-07-19 DOI: 10.1016/j.jmoldx.2024.06.005

Jin Xue , Yingbao Zhu , Yi Pan , Hongjing Huang , Liyi Wei , Ying Peng , Hui Xi , Shihao Zhou , Hongliang Wu , Zhenxiang Gu , Wen Huang , Hua Wang , Ranhui Duan

{"title":"Strategic Implementation of Fragile X Carrier Screening in China","authors":"Jin Xue , Yingbao Zhu , Yi Pan , Hongjing Huang , Liyi Wei , Ying Peng , Hui Xi , Shihao Zhou , Hongliang Wu , Zhenxiang Gu , Wen Huang , Hua Wang , Ranhui Duan","doi":"10.1016/j.jmoldx.2024.06.005","DOIUrl":"10.1016/j.jmoldx.2024.06.005","url":null,"abstract":"<div><p>Fragile X syndrome is the leading genetic cause of intellectual disability and autism spectrum disorders. Female premutation carriers exhibit no obvious symptoms during reproductive age, but the premutation allele can expand to full mutation when transmitted to the fetus. Given the relatively low prevalence but large population, the distinct health care system, the middle-income economic status, and low awareness among public and medical professionals, the optimal genetic screening strategy remains unknown. We conducted a pilot study of Fragile X carrier screening in China, involving 22,245 pregnant women and women with childbearing intentions, divided into control and pilot groups. The prevalence of Fragile X carriers in the control group was 1 of 850, similar to East Asian populations. Strikingly, the prevalence of Fragile X carriers in the pilot group was 1 of 356, which can be attributed to extensive medical training, participant education, and rigorous genetic counseling and testing protocols. Cost-effectiveness analyses of four strategies—no screening, population-based screening, targeted screening, and our pilot screening—indicated that our pilot screening was the most cost-effective option. A follow-up survey revealed that 55% of respondents reported undergoing screening because of their family history. We have successfully established a standardized system, addressing the challenges of low prevalence, limited awareness, and genetic testing complexities. Our study provides practical recommendations for implementing Fragile X carrier screening in China.</p></div>","PeriodicalId":50128,"journal":{"name":"Journal of Molecular Diagnostics","volume":"26 10","pages":"Pages 897-905"},"PeriodicalIF":3.4,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141735542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

DPYD Genotyping Recommendations DPYD 基因分型建议：分子病理学协会、美国医学遗传学和基因组学学院、临床药物遗传学实施联合会、美国病理学家学会、荷兰皇家药剂师协会荷兰药物遗传学工作组、欧洲药物基因组学和个性化治疗学会、药物基因组学知识库和药物基因变异联合会的联合共识建议。

IF 3.4 3区医学

Journal of Molecular Diagnostics Pub Date : 2024-07-18 DOI: 10.1016/j.jmoldx.2024.05.015

Victoria M. Pratt , Larisa H. Cavallari , Makenzie L. Fulmer , Andrea Gaedigk , Houda Hachad , Yuan Ji , Lisa V. Kalman , Reynold C. Ly , Ann M. Moyer , Stuart A. Scott , Amy J. Turner , Ron H.N. van Schaik , Michelle Whirl-Carrillo , Karen E. Weck

{"title":"DPYD Genotyping Recommendations","authors":"Victoria M. Pratt , Larisa H. Cavallari , Makenzie L. Fulmer , Andrea Gaedigk , Houda Hachad , Yuan Ji , Lisa V. Kalman , Reynold C. Ly , Ann M. Moyer , Stuart A. Scott , Amy J. Turner , Ron H.N. van Schaik , Michelle Whirl-Carrillo , Karen E. Weck","doi":"10.1016/j.jmoldx.2024.05.015","DOIUrl":"10.1016/j.jmoldx.2024.05.015","url":null,"abstract":"<div><p>The goals of the Association for Molecular Pathology Clinical Practice Committee's Pharmacogenomics (PGx) Working Group are to define the key attributes of pharmacogenetic alleles recommended for clinical testing and a minimum set of variants that should be included in clinical PGx genotyping assays. This document series provides recommendations for a minimum set of variant alleles (tier 1) and an extended list of variant alleles (tier 2) that will aid clinical laboratories when designing assays for PGx testing. The Association for Molecular Pathology PGx Working Group considered the functional impact of the variant alleles, allele frequencies in multiethnic populations, the availability of reference materials, and other technical considerations for PGx testing when developing these recommendations. The goal of this Working Group is to promote standardization of PGx testing across clinical laboratories. This document will focus on clinical <em>DPYD</em> PGx testing that may be applied to all dihydropyrimidine dehydrogenase–related medications. These recommendations are not to be interpreted as prescriptive but to provide a reference guide.</p></div>","PeriodicalId":50128,"journal":{"name":"Journal of Molecular Diagnostics","volume":"26 10","pages":"Pages 851-863"},"PeriodicalIF":3.4,"publicationDate":"2024-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1525157824001545/pdfft?md5=e0bda1c43cd5d77f5cf6e9737bd1ec28&pid=1-s2.0-S1525157824001545-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141735540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multisite Evaluation and Validation of Optical Genome Mapping for Prenatal Genetic Testing 用于产前基因检测的光学基因组图谱的多点评估和验证。

IF 3.4 3区医学

Journal of Molecular Diagnostics Pub Date : 2024-07-18 DOI: 10.1016/j.jmoldx.2024.06.006

Brynn Levy , Jie Liu , M. Anwar Iqbal , Barbara DuPont , Nikhil Sahajpal , Monique Ho , Jingwei Yu , Sam J. Brody , Mythily Ganapathi , Aleksandar Rajkovic , Teresa A. Smolarek , Fatih Boyar , Peter Bui , Adrian M. Dubuc , Ravindra Kolhe , Roger E. Stevenson

{"title":"Multisite Evaluation and Validation of Optical Genome Mapping for Prenatal Genetic Testing","authors":"Brynn Levy , Jie Liu , M. Anwar Iqbal , Barbara DuPont , Nikhil Sahajpal , Monique Ho , Jingwei Yu , Sam J. Brody , Mythily Ganapathi , Aleksandar Rajkovic , Teresa A. Smolarek , Fatih Boyar , Peter Bui , Adrian M. Dubuc , Ravindra Kolhe , Roger E. Stevenson","doi":"10.1016/j.jmoldx.2024.06.006","DOIUrl":"10.1016/j.jmoldx.2024.06.006","url":null,"abstract":"<div><p>Prenatal diagnostic testing of amniotic fluid, chorionic villi, or more rarely, fetal cord blood is recommended following a positive or unreportable noninvasive cell-free fetal DNA test, abnormal maternal biochemical serum screen, abnormal ultrasound, or increased genetic risk for a cytogenomic abnormality based on family history. Although chromosomal microarray is recommended as the first-tier prenatal diagnostic test, in practice, multiple assays are often assessed in concert to achieve a final diagnostic result. The use of multiple methodologies is costly, time consuming, and labor intensive. Optical genome mapping (OGM) is an emerging technique with application for prenatal diagnosis because of its ability to detect and resolve, in a single assay, all classes of pathogenic cytogenomic aberrations. In an effort to characterize the potential of OGM as a novel alternative to traditional standard of care (SOC) testing of prenatal samples, OGM was performed on a total of 200 samples representing 123 unique cases, which were previously tested with SOC methods (92/123 = 74.7% cases tested with at least two SOCs). OGM demonstrated an overall accuracy of 99.6% when compared with SOC methods, a positive predictive value of 100%, and 100% reproducibility between sites, operators, and instruments. The standardized workflow, cost-effectiveness, and high-resolution cytogenomic analysis demonstrate the potential of OGM to serve as a first-tier test for prenatal diagnosis.</p></div>","PeriodicalId":50128,"journal":{"name":"Journal of Molecular Diagnostics","volume":"26 10","pages":"Pages 906-916"},"PeriodicalIF":3.4,"publicationDate":"2024-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1525157824001570/pdfft?md5=5bf6d88f32dd52ed0a19de6229f626d7&pid=1-s2.0-S1525157824001570-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141735541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0